VANCOUVER, BC / ACCESSWIRE / May 12, 2017 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) had entered into a consulting agreement with Lubow Group (“Lubow”), a Florida Sole Proprietorship, with an effective date of January 12, 2017 ( the “Consulting Agreement”). Pursuant to the Consulting Agreement, after the initial 60 day term of the Consulting Agreement, CVR Medical has the option to pay Lubow the US$60,000 (CDN$82,300) that was due for their consulting services by the issuance of common shares of CVR Medical. The parties have agreed to the payment for the consulting services by way of the issuance of an aggregate of 243,850 common shares of CVR Medical, at a deemed price of $0.3375 per share to Lubow.
The issuance of common shares in payment for the consulting services is subject to the prior approval of the TSX Venture Exchange. All common shares issued in connection with this payment will be subject to a four month hold period under applicable Canadian securities laws.
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888